Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of E2511 in Healthy Subjects
NCT04547361Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of E2511 in Alzheimer's disease (AD) (7 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Treatment-Emergent Adverse Events up to 63 days, Abnormal Laboratory Values up to 63 days and 11 more. Started Sep 2020; status: completed.
02
Drugs
E2511
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04547361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547361.